MedDRA 14.0 Review MedDRA Version Changes General Remarks MedDRA Version 14.0 Specific Changes Version 14.0 Changes Overview Changes in a Nutshell

Similar documents
What s New MedDRA Version 14.0

MedDRA 13.0 Review. General Remarks. Version 13.0 Changes Overview. Changes in a Nutshell. Changes Highlights. MedDRA Version Changes

What s New MedDRA Version 13.1

Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs)

What s New MedDRA Version March

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

MedDRA Overview A Standardized Terminology

What s New MedDRA Version MSSO-DI March 2016

What s New MedDRA Version March

MedDRA Basic Concept

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

MedDRA 10.1 Review. MedDRA Version 10.1 What s coming ahead? MedDRA Version Changes. General Remarks. Terminology Files: What you need to know

What s New MedDRA Version 15.1

Proposed MedDRA Version 17.0 Complex Changes (July 2013)

What s New MedDRA Version 18.0

Implemented MedDRA Version 22.0 Complex Changes (October 2018)

Data Analysis and Query Building with MedDRA

Data Analysis and Query Building with MedDRA

Safety Data Analysis and Query Creation with MedDRA

Farmakovijilans ve MedDRA Pharmacovigilance and MedDRA FARMAKOVİJİLANS ve FARMAKOVİJİLANS UYGULAMALARI EKİM Dr.

Perspective: E2B transmission

MedDRA Coding/ AE Log Item 1 Refresher. ASPIRE Protocol Team Meeting February 10, 2013

Introductory Guide for Standardised MedDRA Queries (SMQs) Version 14.0

Preview of New MedDRA Hierarchy for Medication Errors Coding and Retrieval Considerations

Introductory Guide MedDRA Version 15.0

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

MedDRA DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER

MedDRA: Safety Data Analysis and SMQs

MedDRA Safety Data Analysis and SMQs

Introductory Guide MedDRA Version 18.1

Introductory Guide MedDRA Version 14.0

MedDRA: Safety Data Analysis and SMQs

Introduction to MedDRA

Advanced MedDRA Coding

What Medical Writers Need to Know About MedDRA

MedDRA - International standard for coding safety information. The Golden Triangle

Best practices in VeDDRA coding

Proactivity Proposals

Use of MedDRA in Special Situations

MedDRA Coding and Versioning

WHO-ART. Magnus Wallberg. November 24 th 2009 Dar Es Salaam, Tanzania.

MedDRA 10.0 Review. Terminology Files: What you need to know. MedDRA Version 10.0 Terminology Frequency Distribution

Coding with MedDRA 3/6/2019

Coding with MedDRA. MedDRA trademark is owned by IFPMA on behalf of ICH

Coding with MedDRA. of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA

Summary of Changes to. MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA TERM SELECTION: POINTS TO CONSIDER

Coding with MedDRA 4/22/2015

MedDRA TERM SELECTION: POINTS TO CONSIDER

Coding with MedDRA 3/2/2017

Optum360 Learning: Detailed Instruction for Appropriate ICD-10-CM Coding

MedDRA Term Selection: Latest activities of the Points to Consider Working Group

Case Series Drug Analysis Print Name: Isotretinoin

Episodes of Care Risk Adjustment

MedDRA TERM SELECTION: POINTS TO CONSIDER

MedDRA Coding Quality: How to Avoid Common Pitfalls

Course Outline Introduction to ICD-10 Coding Course

How ICD-10 Affects Radiation Oncology. Presented by, Lashelle Bolton CPC, COC, CPC-I, CPMA

Classification of Neoplasms

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER BRCA1 BRCA2

MedDRA TERM SELECTION: POINTS TO CONSIDER

Data retrieval using the new SMQ Medication Errors

Frequently Asked Questions

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

NCCP Chemotherapy Regimen. Olaparib Monotherapy

Elements for a Public Summary. Overview of disease epidemiology

A chapter by chapter look at the ICD-10-CM code set Coding Tip Sheet

Introductory Guide for Standardised MedDRA Queries (SMQs) Version 18.1

NCCP Chemotherapy Regimen. Ibrutinib Therapy Mantle Cell Lymphoma

Internal Medicine Certification Examination Blueprint

4. ICD-10-PCS is used to code and classify data from hospital inpatient records only. a. diagnosis

Synopsis Style Clinical Study Report SAR ACT sarilumab Version number : 1 (electronic 1.0)

APR-DRG Description Ave Charge

CLINICAL STUDY REPORT SYNOPSIS

Online-Only Supplementary Materials

Clinical Study Synopsis

Rare Diseases Nomenclature and classification

SmartVA Analyze Outputs Interpretation Sheet

UnitedHealth Premium Physician Designation Program Episode Treatment Groups (ETG ) Description and Specialty

Scottish Clinical Coding

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Prophylaxis of acute transplant rejection in patients receiving allogeneic renal transplants:

RADPrimer Curriculum Breast Topics Covered Basic Intermediate 225

Information from Uppsala Monitoring Centre regarding cases in VigiBase

Innovation and Regulatory Review What is JumpStart?

This proposal represents a significant improvement over the previous version.

Adverse Event Terminology and Coding Working Group

Coding with Confidence

TABLE I-1: RESIDENT INFANT DEATHS PER 1,000 LIVE BIRTHS, BY RACE AND ETHNICITY, FLORIDA AND UNITED STATES, CENSUS YEARS AND

Coding with MedDRA. Course Overview

Atrial Fibrillation We support the proposed modifications for atrial fibrillation. November 8, 2018 VIA ELECTRONIC MAIL

Chapter 3 Diseases of the Blood and Bloodforming Organs and Certain Disorders Involving the Immune Mechanism D50-D89

RUBRACA (rucaparib camsylate) oral tablet

Latest Press Release. pancreatic cancer icd10

Lectures 4 Early fetal assessment, screening, ultrasound and treatment modalities during pregnancy. II. Asphyxia and Resuscitation (3 lectures)...

Icd 10 ovarian stroma

Special pediatric considerations are noted when applicable, otherwise adult provisions apply.

Toward a Diagnosis Driven (Dental) Profession through Controlled Terminology

NEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan

Lynparza. Lynparza (olaparib) Description

Transcription:

MedDRA 14.0 Review MedDRA Version Changes General Remarks MedDRA Version 14.0 Specific Changes Version 14.0 Changes Overview Changes in a Nutshell Changes Highlights MedDRA Version 14.0 Terminology Frequency Distribution MedDRA Version 14.1 - What's coming ahead?

MedDRA Changes - General Remarks There are two possible types of changes in the MedDRA terminology: simple change and complex changes. Simple changes are changes to the existing terminology that involve terms at the PT and LLT levels. There are two types of Simple changes: (1) changes introduced by subscribers request and (2) Maintenance changes (also referred to as Associate changes). Maintenance changes are generated as a byproduct of other changes requested by subscribers, or changes introduced by the MedDRA Management Board to preserve consistency within the dictionary. Complex changes involve modifications within the entire hierarchy, including the HLT, HLGT, and SOC terminology. Currently, the initial MedDRA terminology version release in one specific year (12.0, 13.0) includes both simple and complex changes, and the subsequent release in the same year (12.1, 13.1) represents a simple change of terminology. These changes are based on MedDRA subscribers' terminology change requests and on MedDRA terminology maintenance needs identified by MedDRA's maintenance organization reviewers. Please note that as a consequence of implementing some of these changes (e.g. demoting a multiaxial PT, adding a new HLT, etc.) it may be necessary to break the multiaxial links, to re-link the replacement terms, and/or to enable additional terms to be included within a particular SOC. All these changes may require modifications to your existing MedDRA coding, guideline development, and data retrieval practices. Keep in mind that changes involve both MedDRA terminology updates as well as Standardized MedDRA Queries (SMQ). Back to MedDRA 14.0 Review

MedDRA 14.0 Changes: Overview Changes In a Nutshell Complex Changes New Terms and Modified PTs and LLTs Impact Standardized MedDRA Queries (SMQs) Changes Highlights Featured PT Changes s Promoted LLTs Featured LLT Changes New LLTs Demoted PTs Currency changes Back to MedDRA 14.0 Review

Changes In a Nutshell Complex Changes The complex changes implemented in Version 14.0 are summarized below. At the SOC level: No changes were made to existing SOC terms and no new SOCs were added in Version 14.0. At the HLGT level: No changes were made to existing HLGT terms and no new HLGTs were added in Version 14.0. At the HLT level: There were 6 new High Level Terms (HLTs) added, 1 HLT renamed and 5 HLTs merged as a result of the complex changes in Version 14.0. In addition 3 multi-axial HLTs were made uni-axial by removing one of their links. They are as follows: New HLTs Acquired mutations NEC to HLGT General system disorders NEC Disorders of purine metabolism to HLGT Purine and pyrimidine metabolism disorders Disorders of pyrimidine metabolism to HLGT Purine and pyrimidine metabolism disorders Enteroviral infections NEC to HLGT Viral infectious disorders Peritoneal fluid and membrane function analyses to HLGT Gastrointestinal investigations Social issues NEC to HLGT Lifestyle issues Renamed HLTs v13.1 Capnocytophagia infections to Capnocytophaga infections in v14.0 Merged HLTs Enteroviral infections to HLT Enteroviral infections NEC Picornaviral infections to HLT Viral infections NEC Purine metabolism disorders NEC to HLT Disorders of purine metabolism Pyrimidine metabolism disorders NEC to HLT Disorders of pyrimidine metabolism Social issues to HLT Social issues NEC HLT link changes HLT unlinked Purine metabolism disorders congenital from HLGT Purine and pyrimidine metabolism disorders HLT unlinked Pyrimidine metabolism disorders congenital from HLGT Purine and pyrimidine metabolism disorders HLT unlinked Renal disorders congenital from HLGT Renal disorders (excl nephropathies) Back

New Terms and Modified PTs and LLTs Impact As a result of adding the new HLTs, new PTs were added and existing PTs were moved or secondary links established. Some of the following actions occurred: Acquired mutations NEC was added as an HLT under HLGT: General system disorders NEC. HLT Acquired mutations NEC is intended to cover all mutations acquired by a somatic cell after conception. PT Acquired gene mutation, PT Acquired mitochondrial DNA deletion and PT Acquired mitochondrial DNA mutation will be moved to new HLT Acquired mutations NEC. The HLT Social issues will be merged into new HLT Social issues NEC. Substance use will be under this new HLT Social issues NEC. In V13.0 HLT: Picornaviral infections has only one PT Foot and mouth disease; therefore in V14.0 the HLT: Picornaviral infections was merged under HLT: Viral infections NEC. The PT Foot and mouth disease is now appropriately under HLT: Viral infections NEC. Existing HLT: Enteroviral infections will be merged into new HLT: Enteroviral infections NEC. HLT: Enteroviral infections NEC will contain PTs that represent infections which cannot be attributed to the specific serotypes already represented at the HLT level. In addition HLT: Renal disorders congenital (a multi-axial HLT ) was unlinked from HLGT: Renal disorders (excl nephropathies). This change allows for specific placement of congenital renal disorders according to the SOC of the anatomical site of manifestation, and thus groups congenital renal disorders with their counterpart acquired terms. As a result of adding a new HLT: Peritoneal fluid and membrane function analyses to HLGT Gastrointestinal investigations the following PTs : PT: Effective peritoneal surface area increased PT: Peritoneal effluent analysis PT: Peritoneal effluent abnormal PT: Peritoneal effluent erythrocyte count PT: Peritoneal effluent erythrocyte count increased PT: Peritoneal effluent leukocyte count PT: Peritoneal effluent leukocyte count increased PT: Peritoneal effluent platelet count PT: Peritoneal effluent specific gravity PT: Peritoneal fluid analysis

PT: Peritoneal fluid analysis normal PT: Peritoneal fluid analysis abnormal would move from their current HLT: Gastrointestinal histopathology procedures to the new HLT: Peritoneal fluid and membrane function analyses. The PT: Peritoneal equilibration test would move from current HLT: Renal function analyses to the new HLT: Peritoneal fluid and membrane function analyses. Back

Standardized MedDRA Queries (SMQs) There are now 85 level 1 SMQs in production as of this version 14.0 New Developments in Version 14.0: Inactive SMQ In Version 14.0 :SMQ Adverse pregnancy outcome/reproductive toxicity (incl neonatal disorders) was made inactive and replaced with SMQ Pregnancy and neonatal topics (SMQ). List of sub search SMQs in SMQ Pregnancy and neonatal topics: SMQ Congenital, familial and genetic disorders SMQ Foetal disorders SMQ Lactation related topics (incl neonatal exposure through breast milk) SMQ Neonatal disorders SMQ Normal pregnancy conditions and outcomes SMQ Pregnancy, labour and delivery complications and risk factors (excl abortions and stillbirth) SMQ Termination of pregnancy and risk of abortion Renamed SMQ s A total of 4 SMQs were renamed in MedDRA Version 14.0. SMQ Haematopoietic cytopenias affecting more than one type of blood cell from previous SMQ Name: Cytopenia and haematopoietic disorders affecting more than one type of blood cell. SMQ Haematopoietic erythropenia from previous SMQ Name: Erythropenia SMQ Haematopoietic leucopenia from previous SMQ Name: Leukopenia SMQ Haematopoietic thrombocytopenia from previous SMQ Name: Thrombocytopenia Malignant or unspecified SMQs Two new sub-search SMQs have been added to malignant and/or unspecified SMQs to allow users to retrieve malignant only event cases; events/cases of neoplasms of unspecified malignancy or a combination of malignant and unspecified neoplasm events/cases. New sub search SMQs have been added to the following existing SMQs: Biliary neoplasms malignant and unspecified Breast neoplasms, malignant and unspecified Liver neoplasms, malignant and unspecified Malignant or unspecified tumours Ovarian neoplasms, malignant and unspecified Prostate neoplasms, malignant and unspecified Uterine and fallopian tube neoplasms, malignant and unspecified Skin neoplasms, malignant and unspecified

The PTs under the existing Malignant or unspecified SMQs have been moved to the respective malignant only or unspecified malignancy sub search SMQs. SMQ Premalignant disorders 130 PTs in the five sub search SMQs of SMQ Premalignant disorders have been made inactive. In addition all terms in the five sub search SMQs have been made narrow in scope. Back Back to MedDRA 14.0 Review

MedDRA Version 14.0 Specific Changes Changes Highlights Featured PT Changes PT Changes: - 189 new PTs - 23 Promoted LLTs - 45 demoted PTs - Net new 167 PTs Thus making a total of 19,086 PTs in v14.0 Following are several examples: Version 14.0 PT Allergic myocarditis Limbal swelling Device kink Metabolic cardiomyopathy Right ventricular heave Ventricular dyssynchrony Branchio-oto-renal syndrome Congenital hypercoagulation Spina bifida cystica Corneal thickening Eccentric fixation Colon dysplasia Nicotinic stomatitis Capsule physical issue Promoted LLT Promoted LLT Promoted LLT Microsomia Out of specification test results s and Promoted LLTs Back

Featured LLT Changes New LLTs 358 new LLTs Demoted PTs 45 PTs were demoted to LLT level in version 14.0 Currency changes 13 LLTs had a currency change in version 14.0-3 non-current LLTs became current, -10 current LLTs became non-current (examples below) 1 LLT and 5 PTs were modified in version 14.0 (text modification) Thus in version 14.0 there are a total of 69,019 LLTs of which 59,940 are current and 9,079 are non-current. ANF positive APA APA negative APA positive CF positive Device firing issue DU GU Positive ANF Unable to focus Allergy to plants FOB positive LVF LLT Version 14.0 Currency Current Current Current LLT Currency Changes

Level Version 13.1 Version 14.0 code LLT Capnocytophagia Capnocytophaga infection 10007207 infection NOS NOS PT Capnocytophagia Capnocytophaga infection 10061738 infection PT Capnocytophagia test positive Capnocytophaga test positive 10070026 PT Eastern cooperative oncology group performance status Eastern Cooperative Oncology Group performance status 10067961 PT Eastern cooperative oncology group performance status Eastern Cooperative Oncology Group performance improved status improved 10069725 PT Eastern cooperative oncology group performance status Eastern Cooperative Oncology Group performance worsened status worsened 10067962 Modified PT and LLT Names Back Back to MedDRA 14.0 Review

MedDRA Version 14.0 Terminology Frequency Distribution by MedDRA Version Level Version 9.1 Version Version Version Version Version Version Version Version Version 10.0 10.1 11.0 11.1 12.0 12.1 13.0 13.1 14.0 SOC 26 26 26 26 26 26 26 26 26 26 HLGT 332 332 332 332 332 333 333 335 335 335 HLT 1,682 1,682 1,682 1,688 1,688 1,699 1,699 1,709 1,709 1,710 PT 17,505 17,719 17,867 18,075 18,209 18,483 18,641 18,786 18,919 19,086 LLT 64,620 65,147 65,605 66,135 66,587 67,159 67,503 68,258 68,661 69,019 Current LLT's 55,621 56,125 56,580 57,104 57,556 58,124 58,451 59,190 59,589 59,940 LLT's 8,999 9,022 9,025 9,031 9,031 9,035 9,052 9,068 9,072 9,079 Back to MedDRA 14.0 Review

MedDRA Version 14.0 - What's Coming Ahead? The next MedDRA terminology release, version 14.1, is scheduled for September 2011. Back to MedDRA 14.0 Review